Tubbs C - Search Results

1

An evaluation of acuity adjustment metrics to track medication expense over time.

Brink HL, Naseman RW, Porter K, Reed EE, Tubbs C. Brink HL, et al. Among authors: tubbs c. Am J Health Syst Pharm. 2015 Dec 15;72(24):2157-65. doi: 10.2146/ajhp140755. Am J Health Syst Pharm. 2015. PMID: 26637515

2

Implementation of a prioritized scoring tool to improve time to pharmacist intervention.

Harvin A, Mellett JJJ, Knoell D, Mirtallo J, Naseman RW, Brown N, Tubbs CR. Harvin A, et al. Am J Health Syst Pharm. 2018 Jan 1;75(1):e50-e56. doi: 10.2146/ajhp150787. Am J Health Syst Pharm. 2018. PMID: 29273613

3

Comparison of 3 Surveillance Methods to Detect Potential Controlled Substance Diversion in an Academic Medical Center.

Derington CG, Lopez BR, Weber RJ, Tubbs CR. Derington CG, et al. Hosp Pharm. 2020 Oct;55(5):323-331. doi: 10.1177/0018578719844170. Epub 2019 Apr 29. Hosp Pharm. 2020. PMID: 32999502 Free PMC article.

4

Pharmaceutical Cost Savings in the Intensive Care Unit.

Pennell BT, Murphy CV, Byrd C, Tubbs C. Pennell BT, et al. Among authors: tubbs c. Crit Care Nurs Q. 2017 Oct/Dec;40(4):414-423. doi: 10.1097/CNQ.0000000000000177. Crit Care Nurs Q. 2017. PMID: 28834862

5

Factors Associated With Burnout Among US Hospital Clinical Pharmacy Practitioners: Results of a Nationwide Pilot Survey.

Jones GM, Roe NA, Louden L, Tubbs CR. Jones GM, et al. Hosp Pharm. 2017 Dec;52(11):742-751. doi: 10.1177/0018578717732339. Epub 2017 Sep 27. Hosp Pharm. 2017. PMID: 29276254 Free PMC article.

6

Using the plan-do-study-act model to convert to a new insulin delivery system.

Sheldon KA, Seoane-Vazquez E, Szeinbach SL, Tubbs C. Sheldon KA, et al. Among authors: tubbs c. Am J Health Syst Pharm. 2009 Jun 15;66(12):1074-5. doi: 10.2146/ajhp080185. Am J Health Syst Pharm. 2009. PMID: 19498116 No abstract available.

7

Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.

Barrington DA, Haight PJ, Calhoun C, Tubbs C, Cohn DE, Bixel KL. Barrington DA, et al. Among authors: tubbs c. Gynecol Oncol. 2021 Sep;162(3):626-630. doi: 10.1016/j.ygyno.2021.06.014. Epub 2021 Jun 18. Gynecol Oncol. 2021. PMID: 34148720

8

Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis.

Barrington DA, Tubbs C, Smith HJ, Straughn JM Jr, Senter L, Cohn DE. Barrington DA, et al. Among authors: tubbs c. Int J Gynecol Cancer. 2020 Oct;30(10):1569-1575. doi: 10.1136/ijgc-2020-001550. Epub 2020 Aug 4. Int J Gynecol Cancer. 2020. PMID: 32753559

9

Exploring risk and ease of use for insulin delivery by nurses.

Sheldon KA, Seoane-Vazquez E, Szeinbach SL, Tubbs C. Sheldon KA, et al. Among authors: tubbs c. J Eval Clin Pract. 2010 Feb;16(1):199-201. doi: 10.1111/j.1365-2753.2009.01131.x. J Eval Clin Pract. 2010. PMID: 20367834 No abstract available.

10

Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.

Barrington DA, Riedinger C, Haight PJ, Tubbs C, Cohn DE. Barrington DA, et al. Among authors: tubbs c. Gynecol Oncol. 2022 Jun;165(3):500-505. doi: 10.1016/j.ygyno.2022.03.031. Epub 2022 Apr 12. Gynecol Oncol. 2022. PMID: 35422338

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

68 results

Search Page

Filters